Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-acetylcysteine added to risperidone for cognitive deficits in psychotic disorders
IRCT20240309061224N1Phase 3Completed
- Sponsor
- Zanjan University of Medical Sciences
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of acetylcysteine and risperidone in schizophrenia, Schizophrenia Spectrum Disorders (SSD), schizoaffective disorder and 4 more (2 arms), sponsored by Zanjan University of Medical Sciences. Primary endpoints: Positive Symptoms and Negative Symptoms. Started Apr 2024; status: completed.
02
Drugs
acetylcysteinerisperidone
03
Conditions
schizophreniaSchizophrenia Spectrum Disorders (SSD)schizoaffective disorderdelusional disorderschizophreniform disorder
Beyond the preview
Go deeper on IRCT20240309061224N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240309061224N1.